European LeukemiaNet

Discussion is focusing on how European LeukemiaNet (ELN) recommendations are used to stratify risk in acute myeloid leukemia (AML) and to assess patient fitness before treatment. The framework relies on objective genetic and clinical criteria to guide whether patients receive intensive chemotherapy or lower-intensity approaches. Clinicians point to it as a key standard for treatment decisions.